Early Life and Education
Patrick Soon‑Shiong was born on July 29, 1952 in Port Elizabeth, then part of the Union of South Africa (now Eastern Cape, South Africa). He is the son of Soon‑Shiong Soon, a physician of Chinese descent, and Catherine Soon‑Shiong, a housewife. The family moved to Salisbury (now Harare, Zimbabwe) when Patrick was five, and later to Durban, where he attended the prestigious University of Durban-Westville for his secondary schooling. His early exposure to medicine came through his father’s practice, instilling both a fascination with scientific problem‑solving and a respect for patient care.
At age 16, Soon‑Shiong earned a scholarship to study at the University of Witwatersrand in Johannesburg, where he completed a BSc (Honours) in Chemistry (1971) and an MBChB (Bachelor of Medicine, Bachelor of Surgery) in 1976. He subsequently pursued a Ph.D. in molecular pharmacology at the University of the Witwatersrand, completed in 1979, focusing on the metabolic pathways of antineoplastic agents. In 1979 he emigrated to the United States on a research fellowship at the University of California, San Diego (UCSD), where he earned a second Ph.D. in biochemistry under the mentorship of Nobel laureate Dr. Carl Djerassi. During this period, he also completed a surgical residency at the University of Southern California (USC) Keck School of Medicine, finishing in 1986.
First Ventures and Breakthrough
While still a surgical resident, Soon‑Shiong began to explore the commercial potential of his research on the metabolism of chemotherapy drugs. In 1989 he founded a small biotechnology start‑up, New Biologics, which later became the foundation for Pacific Biotech (later re‑branded as Sorrento Therapeutics). The company’s early work on novel drug formulation technologies attracted venture‑capital funding from firms such as Kleiner Perkins and Institutional Venture Partners (IVP). Although New Biologics did not achieve commercial success, it validated Soon‑Shiong’s ability to translate laboratory insights into marketable products.
His breakthrough came in 1995 with the creation of the drug‑delivery platform “Nanoliposomal Irinotecan” (later marketed as Onivyde). By engineering liposome‑encapsulated chemotherapy agents, Soon‑Shiong demonstrated significantly improved pharmacokinetics and reduced systemic toxicity. The product earned FDA approval in 2015, providing a critical revenue stream that funded a series of later acquisitions. This early venture underscored his pattern of leveraging scientific innovation, aligning it with market timing, and securing capital from both private equity and strategic pharmaceutical partners.
Companies, Strategy, and Leadership
In 1995, Soon‑Shiong founded ViroMed, a company focused on targeted drug delivery using viral vectors. ViroMed’s “SmartLipids” technology attracted a $120 million acquisition by Pfizer in 2005, marking the first major exit for the entrepreneur and providing the capital to launch his next phase: immunotherapy and precision‑medicine platforms.
In 2003 he co‑founded Immunology Associates (now NantWorks), a conglomerate that would later encompass more than 30 subsidiaries spanning biotechnology, health‑care delivery, artificial intelligence, and digital media. The NantWorks model is built on a “network‑of‑networks” approach: each subsidiary addresses a niche (e.g., AI‑driven diagnostics, radiology, tele‑medicine) while sharing data, capital, and strategic direction from the central holding company. Key ventures include:
- NantKwest (formerly NantCell): a gene‑editing and cell‑therapy platform focusing on CAR‑T and CRISPR‑based approaches.
- Vir Biotechnology: founded in 2016 with a mission to develop broad‑spectrum antiviral therapies; Soon‑Shiong contributed $140 million in seed capital and served on the board.
- Virtua Health: a California‑based integrated health‑system acquired in 2015 for $2.5 billion, providing a platform for clinical trial access and data collection for NantWorks’ research pipelines.
His leadership style blends scientific rigor with aggressive capital deployment. He is known for “stretch‑goal” financing, often leveraging the prospect of breakthrough therapies to secure large debt financings (e.g., the $2 billion senior loan for the Virtua acquisition). He maintains a hands‑on board presence across subsidiaries, emphasizing data‑centric decision‑making and rapid iteration. The strategy relies heavily on cross‑selling services across the network, positioning NantWorks as both a research engine and a provider of clinical services.
Wealth, Public Image, and Controversies
Estimates of Patrick Soon‑Shiong’s net worth vary. Forbes listed him at approximately US$1.5 billion in 2022, largely derived from his holdings in NantWorks and related private equity stakes. He is also a major private owner of the Los Angeles Times (acquired with family in 2018) and the San Diego Union‑Tribune (acquired in 2019).
His public image is a mix of admiration for scientific ambition and critique over business practices. Critics have raised concerns about:
- Labor relations: Following the Virtua acquisition, employee unions complained about restructuring and layoffs, alleging insufficient integration planning.
- Regulatory scrutiny: In 2017 the FDA issued a “Complete Response Letter” for one of NantKwest’s CAR‑T products, prompting public debate about rushed approvals and safety data transparency.
- Media ownership: Ownership of two prominent newspapers provoked accusations of potential conflicts of interest, especially regarding coverage of health‑care policy.
Despite these controversies, Soon‑Shiong is frequently cited in industry forums for his vision of “medical triannulism” – the integration of research, development, and delivery under one umbrella. He has also been honored with the 2016 Lasker‑Bloomberg Public Service Award and elected to the National Academy of Engineering.
Philanthropy, Legacy, and Industry Impact
Beyond commercial pursuits, Soon‑Shiong founded the Chan Soon-Shiong Family Foundation (CSSFF) in 2002, which focuses on medical research, education, and community health. The foundation has donated more than US$300 million to institutions such as the University of California, San Diego (UCSD) School of Medicine, UCSF, and the Stanford Cancer Institute. Notable contributions include the establishment of the Patrick Soon‑Shiong Center for Cancer Research at the University of Southern California and a $25 million gift to the University of California, Irvine for a new cancer immunotherapy program.
His impact on the health‑care industry is evident in several dimensions:
- Drug‑delivery innovation: The nanoliposomal platforms pioneered by Soon‑Shiong have become a standard approach for improving therapeutic indices of chemotherapeutics.
- Integrated health‑care networks: The Virtua acquisition demonstrated the strategic value of aligning research with patient care delivery, influencing similar models pursued by Kaiser Permanente and Mayo Clinic.
- Accelerated biotech financing: By repeatedly securing large‑scale debt and equity deals, Soon‑Shiong illustrated an alternative to traditional IPO pathways for capital‑intensive biotech firms.
Long‑term, his legacy is likely to be judged on the durability of the NantWorks ecosystem and the measurable outcomes of his philanthropic grants, especially in advancing immunotherapy and precision medicine. Whether his “network‑of‑networks” structure can sustain innovation at scale remains a key question for scholars of modern health‑care entrepreneurship.
